Pages that link to "Q45011772"

The following pages link to Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. (Q45011772):

Displaying 36 items.

• Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders (Q24194034) (← links)
• The use of amisulpride in the treatment of acute psychosis (Q24683055) (← links)
• The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study (Q24800019) (← links)
• Amisulpride: a review of its use in the management of schizophrenia (Q28291252) (← links)
• How to Obtain NNT from Cohen's d: Comparison of Two Methods (Q28740693) (← links)
• Amisulpride for schizophrenia (Q31083696) (← links)
• A critical review of akathisia, and its possible association with suicidal behaviour (Q31116050) (← links)
• The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study (Q33609974) (← links)
• Amisulpride: a review of its use in the management of schizophrenia. (Q34458514) (← links)
• Effects of newer antipsychotics on extrapyramidal function (Q34481227) (← links)
• Spotlight on amisulpride in schizophrenia (Q34558605) (← links)
• Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. (Q34560335) (← links)
• Safety and tolerability of antipsychotics: focus on amisulpride (Q35026487) (← links)
• Management of the negative symptoms of schizophrenia: new treatment options (Q35201017) (← links)
• Quality of life in schizophrenic patients (Q35236921) (← links)
• Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics (Q35873789) (← links)
• Is the superior efficacy of new generation antipsychotics an artifact of LOCF? (Q37076000) (← links)
• Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features (Q37227479) (← links)
• The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study (Q37352336) (← links)
• Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic (Q37418931) (← links)
• rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride (Q38741135) (← links)
• Update on the management of symptoms in schizophrenia: focus on amisulpride (Q41529086) (← links)
• The use of atypical antipsychotics in the long-term care of schizophrenia (Q42171188) (← links)
• Initial experiences with amisulpride, an in Germany novel, atypical neuroleptic drug in treatment of adolescents with psychiatric disorders (Q43721485) (← links)
• Amisulpride is an "atypical" antipsychotic associated with low weight gain (Q44675344) (← links)
• Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders (Q46097656) (← links)
• The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. (Q46670479) (← links)
• On the concept of remission in schizophrenia (Q51901729) (← links)
• The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial (Q51927623) (← links)
• Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). (Q53510568) (← links)
• Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis (Q58760344) (← links)
• The acute and long‐term effectiveness of amisulpride in patients with schizophrenia: results of a 12‐month open‐label prospective follow‐up study (Q60637427) (← links)
• [Pharmacotherapy for schizophrenia] (Q79327220) (← links)
• Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs (Q79744901) (← links)
• Linking the PANSS, BPRS, and CGI: clinical implications (Q79845789) (← links)
• How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials (Q89458401) (← links)